---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-005108"
form_type: "8-K"
ticker: "LPCN"
cik: "0001535955"
company_name: "Lipocine Inc."
filed_at: "2025-02-06T23:59:59+00:00"
generated_at: "2026-05-27T01:38:16.754065+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# FDA requires Phase 3 efficacy/safety study for Lipocine's LPCN 1154 in PPD

## Summary
- FDA advised that an efficacy and safety study in target population is needed for 505(b)(2) NDA submission, beyond prior PK bridge data.
- Lipocine is now planning a Phase 3 safety and efficacy study for oral LPCN 1154 (brexanolone) for postpartum depression.
- CEO stated study could support product labeling, exclusivity for 48-hour oral treatment, and also investigate anxiety disorders.
- Previous expectations were to discuss NDA package in Q1 2025; new guidance adds clinical trial requirement.

## SEC filing metadata
- accession: 0001493152-25-005108
- form_type: 8-K
- ticker: LPCN
- cik: 0001535955
- company_name: Lipocine Inc.
- filed_at: 2025-02-06T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1535955/000149315225005108/0001493152-25-005108-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1535955/000149315225005108/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-005108
- JSON: https://secwatch.observer/filing/0001493152-25-005108.json
- Plain text: https://secwatch.observer/filing/0001493152-25-005108.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.